ALZN
Price
$2.24
Change
+$0.04 (+1.82%)
Updated
Oct 14 closing price
Capitalization
8.44M
Intraday Buy/Sell Signals
ERAS
Price
$2.53
Change
+$0.12 (+4.98%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
683.65M
21 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ALZN vs ERAS

Header iconALZN vs ERAS Comparison
Open Charts ALZN vs ERASBanner chart's image
Alzamend Neuro
Price$2.24
Change+$0.04 (+1.82%)
Volume$34.7K
Capitalization8.44M
Erasca
Price$2.53
Change+$0.12 (+4.98%)
Volume$100
Capitalization683.65M
ALZN vs ERAS Comparison Chart in %
ALZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALZN vs. ERAS commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALZN is a Hold and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (ALZN: $2.24 vs. ERAS: $2.41)
Brand notoriety: ALZN and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALZN: 29% vs. ERAS: 53%
Market capitalization -- ALZN: $8.44M vs. ERAS: $683.65M
ALZN [@Biotechnology] is valued at $8.44M. ERAS’s [@Biotechnology] market capitalization is $683.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALZN’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ALZN’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than ALZN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALZN’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 6 bullish TA indicator(s).

  • ALZN’s TA Score: 4 bullish, 3 bearish.
  • ERAS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than ALZN.

Price Growth

ALZN (@Biotechnology) experienced а -10.04% price change this week, while ERAS (@Biotechnology) price change was -2.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.76%. For the same industry, the average monthly price growth was +13.99%, and the average quarterly price growth was +268.92%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($684M) has a higher market cap than ALZN($8.44M). ERAS YTD gains are higher at: -3.984 vs. ALZN (-78.544). ALZN has higher annual earnings (EBITDA): -6.17M vs. ERAS (-135.93M). ERAS has more cash in the bank: 301M vs. ALZN (5.62M). ALZN has less debt than ERAS: ALZN (301K) vs ERAS (49.4M). ALZN (0) and ERAS (0) have equivalent revenues.
ALZNERASALZN / ERAS
Capitalization8.44M684M1%
EBITDA-6.17M-135.93M5%
Gain YTD-78.544-3.9841,971%
P/E RatioN/AN/A-
Revenue00-
Total Cash5.62M301M2%
Total Debt301K49.4M1%
TECHNICAL ANALYSIS
Technical Analysis
ALZNERAS
RSI
ODDS (%)
N/A
Bearish Trend 8 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 8 days ago
90%
Momentum
ODDS (%)
Bullish Trend 8 days ago
87%
Bullish Trend 8 days ago
81%
MACD
ODDS (%)
N/A
Bullish Trend 8 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 8 days ago
75%
Bullish Trend 8 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
69%
Bullish Trend 8 days ago
80%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 15 days ago
80%
Declines
ODDS (%)
Bearish Trend 23 days ago
90%
Bearish Trend 23 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 8 days ago
84%
Aroon
ODDS (%)
N/A
Bullish Trend 8 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ALZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QIPT2.520.09
+3.70%
Quipt Home Medical Corp
CLNE2.870.10
+3.61%
Clean Energy Fuels Corp
PRK162.005.21
+3.32%
Park National Corp
OKTA89.08-1.06
-1.18%
Okta
GLMD1.44-0.03
-2.04%
Galmed Pharmaceuticals Ltd

ALZN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALZN has been loosely correlated with VRAX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ALZN jumps, then VRAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALZN
1D Price
Change %
ALZN100%
+1.82%
VRAX - ALZN
45%
Loosely correlated
+1.54%
ASBP - ALZN
41%
Loosely correlated
+7.92%
BEIGF - ALZN
37%
Loosely correlated
N/A
ERAS - ALZN
32%
Poorly correlated
+0.42%
BPMUF - ALZN
30%
Poorly correlated
N/A
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+0.42%
XNCR - ERAS
56%
Loosely correlated
-10.96%
OCUL - ERAS
53%
Loosely correlated
-5.23%
RVMD - ERAS
50%
Loosely correlated
-2.56%
IRON - ERAS
50%
Loosely correlated
+1.45%
ACLX - ERAS
48%
Loosely correlated
+1.28%
More